SCHEMBL21137486

SCHEMBL21137486

CN(C=O)c1cnc2c(F)c(Br)c(Cl)cc2c1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
MAPK8 P45983 1/20 0.37
GPR119 Q8TDV5 2/20 0.36
KCNH2 Q12809 2/20 0.36
SUV39H2 Q9H5I1 2/20 0.36
MAP4K4 O95819 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
MAPT P10636 2/20 0.34
POLB P06746 1/20 0.34
CKS1B P61024 1/20 0.34
SKP1 P63208 1/20 0.34
SKP2 Q13309 1/20 0.34
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP3A5 P20815 1/20 0.34
TLR9 Q9NR96 1/20 0.34
RET P07949 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21137524 0.88 GPR119 (0.38) NR1H2NR1H3MAPK8GPR119KCNH2
SCHEMBL21137480 0.87 MAP4K4 (0.40) NR1H2NR1H3GPR119SUV39H2MAP4K4
SCHEMBL21136711 0.84 MAPK8 (0.41) NR1H2NR1H3MAPK8GPR119KCNH2
SCHEMBL16636900 0.83 MAPK8 (0.39) NR1H2NR1H3MAPK8GPR119KCNH2
SCHEMBL16636974 0.82 MAPK8 (0.39) NR1H2NR1H3MAPK8GPR119KCNH2
SCHEMBL20570346 0.82 NR1H2 (0.46) NR1H2NR1H3GPR119KCNH2RET
SCHEMBL21136735 0.82 KCNH2 (0.47) MAPK8GPR119KCNH2MEN1KMT2A
SCHEMBL21137333 0.81 MAPK8 (0.38) NR1H2NR1H3MAPK8GPR119MAP4K4
SCHEMBL16637247 0.80 USP2 (0.49) MEN1KMT2AMAPT
SCHEMBL20571090 0.79 NR1H2 (0.43) NR1H2NR1H3GPR119KCNH2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019110751-A1 TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS ASTRAZENECA AB (SE) 2019-06-13 WO disclosed